126 related articles for article (PubMed ID: 35478310)
1. Production and Conjugation of Truncated Recombinant Diphtheria Toxin to VEGFR-2 Specific Nanobody and Evaluation of its Cytotoxic Effect on PC-3 Cell Line.
Shajari S; Farajollahi MM; Behdani M; Tarighi P
Mol Biotechnol; 2022 Nov; 64(11):1218-1226. PubMed ID: 35478310
[TBL] [Abstract][Full Text] [Related]
2. A Novel Immunotoxin Targeting Epithelial Cell Adhesion Molecule Using Single Domain Antibody Fused to Diphtheria Toxin.
Roshan R; Naderi S; Behdani M; Ahangari Cohan R; Kazemi-Lomedasht F
Mol Biotechnol; 2023 Apr; 65(4):637-644. PubMed ID: 36129635
[TBL] [Abstract][Full Text] [Related]
3. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of neovascularisation in human endothelial cells using anti NRP-1 nanobody fused to truncated form of diphtheria toxin as a novel immunotoxin.
Naderi S; Roshan R; Behdani M; Kazemi-Lomedasht F
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):230-238. PubMed ID: 33657977
[TBL] [Abstract][Full Text] [Related]
5.
Mousavi A; Sabouri A; Hassanzadeh Eskafi A; Alirahimi E; Kazemi-Lomedasht F; Ghaderi H; Behdani M
Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):113-117. PubMed ID: 34076502
[TBL] [Abstract][Full Text] [Related]
6. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
[TBL] [Abstract][Full Text] [Related]
7. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent.
Shafiee F; Rabbani M; Jahanian-Najafabadi A
J Microbiol Methods; 2016 Nov; 130():100-105. PubMed ID: 27609715
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxins and nanobody-based immunotoxins: review and update.
Khirehgesh MR; Sharifi J; Safari F; Akbari B
J Drug Target; 2021 Sep; 29(8):848-862. PubMed ID: 33615933
[TBL] [Abstract][Full Text] [Related]
9. Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv.
Wang Z; Kim GB; Woo JH; Liu YY; Mathias A; Stavrou S; Neville DM
Bioconjug Chem; 2007; 18(3):947-55. PubMed ID: 17352456
[TBL] [Abstract][Full Text] [Related]
10. Genetic construction and characterization of an anti-monkey CD3 single-chain immunotoxin with a truncated diphtheria toxin.
Ma S; Hu H; Thompson J; Stavrou S; Scharff J; Neville DM
Bioconjug Chem; 1997; 8(5):695-701. PubMed ID: 9327133
[TBL] [Abstract][Full Text] [Related]
11. Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin.
Wang Z; Duran-Struuck R; Crepeau R; Matar A; Hanekamp I; Srinivasan S; Neville DM; Sachs DH; Huang CA
Bioconjug Chem; 2011 Oct; 22(10):2014-20. PubMed ID: 21866954
[TBL] [Abstract][Full Text] [Related]
12. Diphtheria toxin-derived, anti-PD-1 immunotoxin, a potent and practical tool to selectively deplete PD-1
Zhang T; Dong S; Zhai Y; Naatz L; Zhou Z; Chen M
Protein Sci; 2023 Sep; 32(9):e4741. PubMed ID: 37515422
[TBL] [Abstract][Full Text] [Related]
13. A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin.
Chaudhary VK; Gallo MG; FitzGerald DJ; Pastan I
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9491-4. PubMed ID: 2251289
[TBL] [Abstract][Full Text] [Related]
14. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential.
Yu Y; Li J; Zhu X; Tang X; Bao Y; Sun X; Huang Y; Tian F; Liu X; Yang L
Int J Nanomedicine; 2017; 12():1969-1983. PubMed ID: 28331319
[TBL] [Abstract][Full Text] [Related]
15. A novel method to purify immunotoxins from free antibodies using modified recombinant toxins.
Dhanabal M; Fryxell DK; Ramakrishnan S
J Immunol Methods; 1995 Jun; 182(2):165-75. PubMed ID: 7790724
[TBL] [Abstract][Full Text] [Related]
16. Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth.
Behdani M; Zeinali S; Karimipour M; Khanahmad H; Schoonooghe S; Aslemarz A; Seyed N; Moazami-Godarzi R; Baniahmad F; Habibi-Anbouhi M; Hassanzadeh-Ghassabeh G; Muyldermans S
N Biotechnol; 2013 Jan; 30(2):205-9. PubMed ID: 23031816
[TBL] [Abstract][Full Text] [Related]
17. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.
Schmohl JU; Todhunter D; Taras E; Bachanova V; Vallera DA
Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316610
[TBL] [Abstract][Full Text] [Related]
18. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion.
Thompson J; Stavrou S; Weetall M; Hexham JM; Digan ME; Wang Z; Woo JH; Yu Y; Mathias A; Liu YY; Ma S; Gordienko I; Lake P; Neville DM
Protein Eng; 2001 Dec; 14(12):1035-41. PubMed ID: 11809934
[TBL] [Abstract][Full Text] [Related]
19. Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment.
Matar AJ; Pathiraja V; Wang Z; Duran-Struuck R; Gusha A; Crepeau R; Tasaki M; Sachs DH; Huang CA
Transpl Immunol; 2012 Aug; 27(1):52-4. PubMed ID: 22676970
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxin FN18-CRM9 induces stronger T cell signaling than unconjugated monoclonal antibody FN18.
Hamawy MM; Tsuchida M; Cho CS; Manthei ER; Fechner JH; Knechtle SJ
Transplantation; 2001 Aug; 72(3):496-503. PubMed ID: 11502982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
